Vetr Crowd Urges Sell For Impax Laboratories

Loading...
Loading...

The Vetr crowd downgraded its rating for Impax Laboratories Inc IPXL from 5 stars (Strong Buy), issued two days ago, to 1 star (Strong Sell). Crowd sentiment at the time of the downgrade was still generally positive, with 62 percent of Vetr user ratings bullish.

The sharp downgrade in the pharmaceutical company's rating comes the same day as its stock reached a recent level of resistance below the $13.75 mark. The stock hit a sharp upswing at the end of March, jumping more than 47 percent after the company named a new CEO. This following a period of uncertainty when Reuters reported Impax was working with Morgan Stanley to review strategic options for the company's future, including potential acquisition.

Since naming its new CEO, Impax has fluctuated primarily between the $12.50 and $13.50 levels. The stock closed the April 24 trading day at $13.55, slightly above its previous close of $13.50.

Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for Impax is down at $10.55, which is well below the average analyst target price of $19.92. Less than 2 percent of Vetr users are holding IPXL in their watch lists.

Posted In: BiotechDowngradesPrice TargetCrowdsourcingAnalyst RatingsVetr
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...